Story

Harvard Bioscience Stock Gains on Q2 Earnings Beat, Raised Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
Harvard Bioscience Stock Gains on Q2 Earnings Beat, Raised Guidance
Text size
Background

Shares of Harvard Bioscience, Inc. (NASDAQ: HBIO) rose in trading after the company announced second-quarter financial results that exceeded market expectations and raised its full-year forecast.

Quarterly Performance Beats Expectations

For the second quarter of 2026, the Holliston, Massachusetts-based company reported revenue of $22.7 million, an increase of 11% compared to the same period last year. The company posted an adjusted loss per share of -$0.14, which was significantly better than the consensus analyst estimate of a -$0.38 loss.

Adjusted EBITDA, a key measure of profitability, improved to $1.7 million from $1.5 million in the prior-year quarter. While the net loss for the quarter widened to $2.9 million, the net loss for the first half of 2026 narrowed sharply to $6.3 million from $52.6 million a year ago, a figure that was heavily impacted by a large goodwill impairment charge in the prior period.

Upgraded Full-Year Outlook

Alongside its earnings beat, Harvard Bioscience provided an optimistic update to its financial guidance for the full year 2026. The company now anticipates:

Sample IUX Markets – In-articleAd
  • Full-year revenue growth of 3% to 5%.
  • Adjusted gross margin between 57% and 59%.
  • Adjusted EBITDA growth of 6% to 10%.

For the upcoming third quarter of 2026, the company projects revenue in the range of $21.0 million to $22.6 million and adjusted EBITDA between $1.5 million and $2.5 million.

Context for Investors

The positive results and upgraded forecast suggest a strengthening recovery for the company following a difficult prior year. The performance is particularly notable given the broader headwinds facing the life sciences tools sector, including uncertainty around National Institutes of Health (NIH) funding and ongoing tariff pressures.

For investors, the combination of a substantial earnings beat, improving profitability metrics, and a raised full-year outlook provided a clear catalyst for the stock's advance. The upward revision to guidance signals management's growing confidence in its operational and financial trajectory.

Read next

More on Stocks
Back to latest news

LATEST